American Century Companies Inc. Boosts Position in Teladoc Health, Inc. $TDOC

American Century Companies Inc. increased its stake in Teladoc Health, Inc. (NYSE:TDOC) by 78.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 375,050 shares of the health services provider’s stock after buying an additional 165,332 shares during the period. American Century Companies Inc. owned 0.21% of Teladoc Health worth $2,985,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Mercer Global Advisors Inc. ADV increased its stake in Teladoc Health by 9.6% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 12,456 shares of the health services provider’s stock worth $113,000 after buying an additional 1,089 shares during the period. Vise Technologies Inc. increased its position in Teladoc Health by 4.9% during the 4th quarter. Vise Technologies Inc. now owns 30,179 shares of the health services provider’s stock valued at $274,000 after purchasing an additional 1,405 shares during the period. Westside Investment Management Inc. increased its position in Teladoc Health by 16.8% during the 1st quarter. Westside Investment Management Inc. now owns 10,750 shares of the health services provider’s stock valued at $86,000 after purchasing an additional 1,550 shares during the period. National Bank of Canada FI increased its position in Teladoc Health by 79.4% during the 1st quarter. National Bank of Canada FI now owns 3,571 shares of the health services provider’s stock valued at $28,000 after purchasing an additional 1,581 shares during the period. Finally, Golden State Wealth Management LLC increased its position in Teladoc Health by 102.6% during the 1st quarter. Golden State Wealth Management LLC now owns 3,337 shares of the health services provider’s stock valued at $27,000 after purchasing an additional 1,690 shares during the period. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TDOC. Mizuho began coverage on shares of Teladoc Health in a research report on Friday, July 25th. They set a “neutral” rating and a $10.00 target price on the stock. Bank of America cut their target price on shares of Teladoc Health from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 28th. Evercore ISI raised their target price on shares of Teladoc Health from $7.00 to $8.00 and gave the company an “in-line” rating in a research report on Wednesday, July 9th. Wells Fargo & Company cut their target price on shares of Teladoc Health from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 8th. Finally, Truist Financial cut their price objective on shares of Teladoc Health from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Tuesday, May 27th. Six research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $9.80.

Teladoc Health Price Performance

Shares of TDOC opened at $7.74 on Friday. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -6.50 and a beta of 1.76. Teladoc Health, Inc. has a twelve month low of $6.35 and a twelve month high of $15.21. The company has a quick ratio of 2.58, a current ratio of 2.67 and a debt-to-equity ratio of 0.70. The company has a 50 day moving average of $7.81 and a two-hundred day moving average of $8.03.

Teladoc Health (NYSE:TDOC) last released its earnings results on Tuesday, July 29th. The health services provider reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.08. The company had revenue of $631.90 million during the quarter, compared to analysts’ expectations of $621.91 million. Teladoc Health had a negative net margin of 8.16% and a negative return on equity of 10.13%. Teladoc Health’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the business earned ($0.38) EPS. Teladoc Health has set its Q3 2025 guidance at -0.350–0.200 EPS. FY 2025 guidance at -1.350–1.000 EPS. As a group, analysts predict that Teladoc Health, Inc. will post -1.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Adam C. Vandervoort sold 5,808 shares of Teladoc Health stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $6.86, for a total value of $39,842.88. Following the completion of the sale, the insider directly owned 69,773 shares in the company, valued at $478,642.78. This trade represents a 7.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Carlos Nueno sold 3,958 shares of Teladoc Health stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $6.86, for a total transaction of $27,151.88. Following the completion of the sale, the insider owned 17,645 shares of the company’s stock, valued at $121,044.70. This trade represents a 18.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,656 shares of company stock worth $128,189 in the last three months. Corporate insiders own 0.58% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.